The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview
Abstract
PURPOSE AND METHODS: For more than three decades, the therapeutic options for patients with advanced colorectal cancer have almost exclusively been based on fluoropyrimidines. With the recognition that topoisomerase-I (TOP-I) is an important therapeutic target in cancer therapy, irinotecan, a semisynthetic TOP-I–interactive camptothecin derivative, has been clinically established in the treatment of colorectal cancer. RESULTS: Irinotecan was investigated as second-line chemotherapy after prior treatment with fluorouracil (FU)-based regimens in two large randomized phase III trials comparing irinotecan with either best supportive care or an infusional FU/leucovorin (LV) regimen. The outcomes of these trials established irinotecan as the standard therapy in the second-line treatment of colorectal cancer. The therapeutic value of irinotecan in the first-line treatment of metastatic colorectal cancer was investigated in two large randomized phase III trials comparing the combination of irinotecan and FU/LV with FU/LV alone. Both trials demonstrated significant superior efficacy for the combination of irinotecan and FU/LV in terms of response rate, median time to disease progression, and median survival time. Consequently, the combination of irinotecan and FU/LV has been approved as first-line chemotherapy for patients with metastatic colorectal cancer and constitutes the reference therapy against which other treatment options must be tested in the future. CONCLUSION: In this review, the clinical rationale and update of the present clinical status of irinotecan in the treatment of colorectal cancer and future prospects of irinotecan-based combinations are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Wang, J. C. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.003223 · Cited by 1,832
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Hsiang, Y. H., Lihou, M. G., & Liu, L. F. (1989) · PubMed · Cited by 1,028
Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03085-2 · Cited by 992
Crystal Structures of Human Topoisomerase I in Covalent and Noncovalent Complexes with DNA
Redinbo, M. R., Stewart, L., Kuhn, P., Champoux, J. J., & Hol, W. G. J. (1998) · Science · doi:10.1126/science.279.5356.1504 · Cited by 889
Hsiang, Y. H., & Liu, L. F. (1988) · PubMed · Cited by 841
DNA Topoisomerases: Essential Enzymes and Lethal Targets
Chen, A. Y., & Liu, L. F. (1994) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.34.040194.001203 · Cited by 737
A Model for the Mechanism of Human Topoisomerase I
Stewart, L., Redinbo, M. R., Qiu, X., Hol, W. G. J., & Champoux, J. J. (1998) · Science · doi:10.1126/science.279.5356.1534 · Cited by 717
DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in Xenografts
Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., & Potmesil, M. (1989) · Science · doi:10.1126/science.2555920 · Cited by 650
Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
Pommier, Y., Pourquier, P., Fan, Y., & Strumberg, D. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00129-8 · Cited by 551
Mechanism of Action of Camptothecin
Liu, L. F., Duann, P., Lin, C., D'Arpa, P., & Wu, J. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb26375.x · Cited by 508
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., & Ratain, M. J. (1994) · PubMed · Cited by 501
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Maliepaard, M., van Gastelen, M. A., de Jong, L. A., Pluim, D., van Waardenburg, R. C., Ruevekamp, M. C., Floot, B. G., & Schellens, J. H. M. (1999) · PubMed · Cited by 487
Rougier, P., Bugat, R., Douillard, J. Y., Culine, S., Suc, E., Brunet, P., Becouarn, Y., Ychou, M., Marty, M., Extra, J. M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.251 · Cited by 434
Houghton, P. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., & Houghton, J. A. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686188 · Cited by 401
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Rothenberg, M. L., Eckardt, J. R., Kuhn, J. G., Burris, H. A., Nelson, J., Hilsenbeck, S. G., Rodriguez, G. I., Thurman, A. M., Smith, L. S., Eckhardt, S. G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.4.1128 · Cited by 352
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
Conti, J. A., Kemeny, N. E., Saltz, L. B., Huang, Y., Tong, W. P., Chou, T. C., Sun, M., Pulliam, S., & Gonzalez, C. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.709 · Cited by 344
Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., Yokoi, T., & Kamataki, T. (1996) · PubMed · Cited by 336
Topoisomerase I inhibitors: Review and update
Rothenberg, M. L. (1997) · Annals of Oncology · doi:10.1023/a:1008270717294 · Cited by 306
Slatter, J. G., Schaaf, L. J., Sams, J. P., Feenstra, K. L., Johnson, M. G., Bombardt, P. A., Cathcart, K. S., Verburg, M. T., Pearson, L. K., Compton, L. D., et al. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15060-x · Cited by 302
Phase I and pharmacokinetic trial of weekly CPT-11.
Rothenberg, M. L., Kuhn, J. G., Burris, H. A., Nelson, J., Eckardt, J. R., Tristan-Morales, M., Hilsenbeck, S. G., Weiss, G. R., Smith, L. S., & Rodriguez, G. I. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2194 · Cited by 301
Abigerges, D., Chabot, G. G., Armand, J. P., Hérait, P., Gouyette, A., & Gandia, D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.210 · Cited by 299
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
Andoh, T., Ishii, K., Suzuki, Y., Ikegami, Y., Kusunoki, Y., Takemoto, Y., & Okada, K. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5565 · Cited by 287
Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes.
Zhang, H., Wang, J. C., & Liu, L. F. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.4.1060 · Cited by 284
Negoro, S., Fukuoka, M., Masuda, N., Takada, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Niitani, H., & Taguchi, T. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.16.1164 · Cited by 274
Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin
Desai, S. D., Liu, L. F., Vazquez-Abad, D., & D'Arpa, P. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24159 · Cited by 269
André, T., Louvet, C., Maindrault-Goebel, F., Couteau, C., Mabro, M., Lotz, J. P., Gilles-Amar, V, Krulik, M., Carola, E., Izrael, V, et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00150-1 · Cited by 267
Brangi, M., Litman, T., Ciotti, M., Nishiyama, K., Kohlhagen, G., Takimoto, C. H. M., Robey, R. W., Pommier, Y. G., Fojo, T., & Bates, S. E. (1999) · PubMed · Cited by 263
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
Pitot, H. C., Wender, D. B., O'Connell, M. J., Schroeder, G., Goldberg, R. M., Rubin, J., Mailliard, J. A., Knost, J. A., Ghosh, C., Kirschling, R. J., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2910 · Cited by 258
Irinotecan (CPT-11) High-Dose Escalation Using Intensive High-Dose Loperamide to Control Diarrhea
Abigerges, D., Armand, J.-P., Chabot, G. G., Costa, L. D., Fadel, E., Cote, C., Herait, P., & Gandia, D. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.6.446 · Cited by 248
Covey, J. M., Jaxel, C., Kohn, K. W., & Pommier, Y. (1989) · PubMed · Cited by 245
Husain, I., Mohler, J. L., Seigler, H. F., & Besterman, J. M. (1994) · PubMed · Cited by 244
Furman, W. L., Stewart, C. F., Poquette, C. A., Pratt, C. B., Santana, V. M., Zamboni, W. C., Bowman, L. C., Ma, M. K., Hoffer, F. A., Meyer, W. H., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1815 · Cited by 235
Rivory, L. P., Bowles, M. R., Robert, J., & Pond, S. M. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00457-1 · Cited by 228
Ryan, A. J., Squires, S., Strutt, H. L., & Johnson, R. T. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.12.3295 · Cited by 227
Sugimoto, Y., Tsukahara, S., Oh‐hara, T., Isoe, T., & TSURUO, T. (1990) · PubMed · Cited by 223
Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports
Wasserman, E., Myara, A., Lokiec, F., Goldwasser, F., Trivin, F., Mahjoubi, M., Misset, J. L., & Cvitkovic, E. (1997) · Annals of Oncology · doi:10.1023/a:1008261821434 · Cited by 213
Camptothecins: a review of their development and schedules of administration
O’Leary, J., & Muggia, F. M. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00229-9 · Cited by 212
Hendricks, C. B., Rowinsky, E. K., Grochow, L. B., Donehower, R. C., & Kaufmann, S. H. (1992) · PubMed · Cited by 210
Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors
Pommier, Y., Pharm, D., Fesen, M. R., Fujimori, A., Bertrand, R., Solary, E., Kohlhagen, G., & Kohn, K. W. (1994) · Cancer Investigation · doi:10.3109/07357909409021413 · Cited by 207
Tsao, Y., Russo, A. A., Nyamuswa, G., SILBER, R. H., & Liu, L. F. (1993) · PubMed · Cited by 206
Rothenberg, M. L., Cox, J. V., DeVore, R. F., Hainsworth, J. D., Pazdur, R., Rivkin, S. E., Macdonald, J. S., Geyer, C. E., Sandbach, J., Wolf, D. L., et al. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990215)85:4<786::aid-cncr5>3.0.co;2-9 · Cited by 201
Rowinsky, E. K., Grochow, L. B., Ettinger, D. S., Sartorius, S. E., Lubejko, B. G., Chen, T. L., Rock, M. K., & Donehower, R. C. (1994) · PubMed · Cited by 194
Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.
Rustum, Y. M., Harstrick, A., Cao, S., Vanhoefer, U., Yin, M. B., Wilke, H., & Seeber, S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.389 · Cited by 192
Self-citationGupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Vokes, E. E., & Ratain, M. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1502 · Cited by 182
The ATM protein is required for sustained activation of NF-κB following DNA damage
Piret, B., Schoonbroodt, S., & Piette, J. (1999) · Oncogene · doi:10.1038/sj.onc.1202541 · Cited by 176
SATOH, T., HOSOKAWA, M., ATSUMI, R., SUZUKI, W., HAKUSUI, H., & NAGAI, E. (1994) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.17.662 · Cited by 174
Molecular Modeling Studies of the DNA−Topoisomerase I Ternary Cleavable Complex with Camptothecin
Fan, Y., Weinstein, J. N., Kohn, K. W., Shi, L. M., & Pommier, Y. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9605445 · Cited by 173
Chabot, G. G., Abigerges, D., Catimel, G., Culine, S., de Forni, M., Extra, J.-M., Mahjoubi, M., Hérait, P., Armand, J.-P., Bugat, R., et al. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059109 · Cited by 173
Tan, K. B., Mattern, M. R., Eng, W.-K., McCabe, F. L., & Johnson, R. K. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.22.1732 · Cited by 171
Recommended guidelines for the treatment of chemotherapy-induced diarrhea.
Wadler, S., Benson, A. B., Engelking, C., Catalano, R., Field, M., Kornblau, S. M., Mitchell, E., Rubin, J., Trotta, P., & Vokes, E. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3169 · Cited by 164
Houghton, P. J., Cheshire, P. J., Hallman, J. C., Bissery, M.-C., Mathieu-Boué, A., & Houghton, J. A. (1993) · PubMed · Cited by 161
Goldwasser, F., Bae, I., Valenti, M. R., Torres, K. E., & Pommier, Y. G. (1995) · PubMed · Cited by 155
Fujimori, A., Harker, W. G., Kohlhagen, G., Hoki, Y., & Pommier, Y. G. (1995) · PubMed · Cited by 151
Forni, M. D., Bugat, R., Chabot, G. G., Culine, S., Extra, J.-M., Gouyette, A., Madelaine, I., Marty, M. E., & Mathieu-Boué, A. (1994) · PubMed · Cited by 150
Saltz, L. B., Kanowitz, J., Kemeny, N. E., Schaaf, L. J., Spriggs, D. R., Staton, B. A., Berkery, R., Steger, C., Eng, M., Dietz, A. B., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.11.2959 · Cited by 145
Rivory, L. P., Haaz, M., Canal, P., Lokiec, F. M., Armand, J., & Robert, J. (1997) · PubMed · Cited by 136
Machover, D. (1997) · Cancer · Cited by 135
Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines.
Sugimoto, Y., Tsukahara, S., Oh‐hara, T., Liu, L. F., & TSURUO, T. (1990) · PubMed · Cited by 134
Wasserman, E., Cuvier, C., Lokiec, F. M., Goldwasser, F., Kalla, S., Méry-Mignard, D., Ould-Kaci, M., Besmaine, A., Dupont-André, G., Mahjoubi, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1751 · Cited by 134
Wiseman, L. R., & Markham, A. (1996) · Drugs · doi:10.2165/00003495-199652040-00013 · Cited by 132
Eng, W.-K., McCabe, F. L., Tan, K. B., et al. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09473-8 · Cited by 127
Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion
Ohe, Y., Sasaki, Y., Shinkai, T., Eguchi, K., Tamura, T., Kojima, A., Kunikane, H., Okamoto, H., Karato, A., Ohmatsu, H., et al. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.12.972 · Cited by 122
Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., Yokoi, T., & Kamataki, T. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050818 · Cited by 120
Jansen, W. J. M., Zwart, B., Hulscher, S. T. M., Giaccone, G., Pinedo, H. M., & Boven, E. (1997) · International Journal of Cancer · Cited by 119
van der Zee, A. G. J., Hollema, H., de Jong, S., Boonstra, H., Gouw, A., Willemse, P. H. B., Zijlstra, J. G., & de Vries, E. G. E. (1991) · PubMed · Cited by 118
A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
Blaney, S. M., Berg, S. L., Pratt, C. B., Weitman, S., Sullivan, J., Luchtman‐Jones, L., & Bernstein, M. L. (2001) · PubMed · Cited by 117
Irinotecan (CPT-11) metabolism and disposition in cancer patients.
Sparreboom, A., de Jonge, M. J., de Bruijn, P., Brouwer, E., Nooter, K., Loos, W. J., van Alphen, R. J., Mathijssen, R. H. J., Stoter, G., & Verweij, J. (1998) · PubMed · Cited by 115
Zeghari, N., Raymond, É., Cvitkovic, E., & Goldwasser, F. (1999) · PubMed · Cited by 115
Catimel, G., Chabot, G. G., Guastalla, J., Dumortier, A., Cote, C., Engel, C., Gouyette, A., Mathieu-Boué, A., Mahjoubi, M., & Clavel, M. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059108 · Cited by 111
Canal, P., Gay, C., Dezeuze, A., Douillard, J., Bugat, R., Brunet, R., Adenis, A., Herait, P., Lokiec, F. M., & Mathieu-Boué, A. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2688 · Cited by 108
Guichard, S. M., Hennebelle, I., Bugat, R., & Canal, P. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00541-8 · Cited by 107
Modulation of DNA Topoisomerase I Activity by p53
Gobert, C., Bracco, L. P., Rossi, F., Olivier, M., Tazi, J., Lavelle, F., Larsen, A. K., & Riou, J. (1996) · Biochemistry · doi:10.1021/bi952327w · Cited by 102
CPT-11 in gastrointestinal cancer
Bleiberg, H. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00423-7 · Cited by 102
Benedetti, P., Fiorani, P., Capuani, L., & Wang, J. C. (1993) · PubMed · Cited by 102
Mans, D. R. A., Grivicich, I., Peters, G. J., & Schwartsmann, G. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00222-1 · Cited by 99
Rivory, L. P., Chatelut, É., Canal, P., Mathieu-Boué, A., & Robert, J. (1994) · PubMed · Cited by 98
Ducreux, M. P., Ychou, M., Seitz, J., Bonnay, M., Bexon, A. S., Armand, J., Mahjoubi, M., Méry-Mignard, D., & Rougier, P. R. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2901 · Cited by 98
Guichard, S. M., Cussac, D., Hennebelle, I., Bugat, R., & Canal, P. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971127)73:5<729::aid-ijc20>3.0.co;2-# · Cited by 93
Freyer, G., Rougier, P. R., Bugat, R., Droz, J., Marty, M. E., Bleiberg, H., Mignard, D., Awad, L., Herait, P., Culine, S., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1303 · Cited by 91
Yang, J. C., Horton, J. K., Cowan, K. H., & Schneider, E. (1995) · PubMed · Cited by 89
Vanhoefer, U. J., Harstrick, A., Köhne, C., Achterrath, W., Rustum, Y. M., Seeber, S., & Wilke, H. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.907 · Cited by 83
Self-citationMullany, S. A., Svingen, P. A., Kaufmann, S. H., & Erlichman, C. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050835 · Cited by 77
Pavillard, V., Formento, P., Rostagno, P., Formento, J., Fischel, J., Francoual, M., Étienne-Grimaldi, M.-C., & Milano, G. A. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00205-6 · Cited by 67
Cao, S., Black, J. D., Troutt, A. B., & Rustum, Y. M. (1998) · PubMed · Cited by 62
Self-citationHerben, V. M. M., Schellens, J. H. M., Swart, M., Gruia, G., Vernillet, L., Beijnen, J. H., & Huinink, W. W. T. B. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1897 · Cited by 58
Jansen, W., Hulscher, T. M., van Ark-Otte, J., Giaccone, G., Pinedo, H. M., & Boven, E. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.58 · Cited by 58
Structure of the human type I DNA topoisomerase gene
Kunze, N., Yang, G. C., DÖLBERG, M., Sundarp, R., Knippers, R., & Richter, A. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)92864-4 · Cited by 57
Takimoto, C. H. M., Morrison, G., Harold, N., Quinn, M. G., Monahan, B. P., Band, R. A., Cottrell, J., Guemei, A. A. S., Llorens, V., Hehman, H., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.659 · Cited by 57
Merrouche, Y., Extra, J.-M., Abigerges, D., Bugat, R., Catimel, G., Suc, E., Marty, M. E., Herait, P., Mahjoubi, M., & Armand, J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1080 · Cited by 55
The Role of Glucuronidation in 7‐Ethyl‐10‐hydroxycamptothecin Resistance in vitro
Takahashi, T., Fujiwara, Y., Yamakido, M., Katoh, O., Watanabe, H., & Mackenzie, P. I. (1997) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1997.tb00351.x · Cited by 54
Gene expression in regenerating liver in relation to cell proliferation and stress
Sobczak‐Thépot, J., Blanchet-Tournier, M.-F., LOTTI, A., & Duguet, M. (1989) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1989.tb14613.x · Cited by 53
Effects of DNA methylation on topoisomerase I and II cleavage activities.
Leteurtre, F., Kohlhagen, G., Fesen, M. R., Tanizawa, A., Kohn, K. W., & Pommier, Y. G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37135-1 · Cited by 48
Guo, B., Cao, S., Tóth, K., Azrak, R. G., & Rustum, Y. M. (2000) · PubMed · Cited by 47
Self-citationKojima, A., Hackett, N. R., & Crystal, R. G. (1998) · PubMed · Cited by 43
Tomonaga, M., Oka, M., 楢崎, 史., Fukuda, M., Nakano, R., Takatani, H., Ikeda, K., Terashi, K., Matsuo, I., Soda, H., et al. (1996) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1996.tb03142.x · Cited by 41
Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I
Gromova, I., Kjeldsen, E., Svejstrup, J. Q., Alsner, J., Christiansen, K., & Westergaard, O. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.3.593 · Cited by 37
Scheithauer, W., Kornek, G. V., Brugger, S. A., Ullrich-Pur, H., Valencak, J., Raderer, M., Fiebiger, W., Kovats, E., Lang, F., & Depisch, D. (2002) · Cancer Investigation · doi:10.1081/cnv-120000367 · Cited by 27
Comella, P., Casaretti, R., Vita, F. D., Avallone, A., Orditura, M., Petrillo, A., Gravina, A., Faranda, A., Comis, S., Comella, G., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008339010655 · Cited by 16
The Human Topoisomerase I Gene Promoter Is Regulated by NF-IL6
Heiland, S., & Knippers, R. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6623 · Cited by 16
Guo, B., Yin, M. B., Tóth, K., Cao, S., Azrak, R. G., & Rustum, Y. M. (1999) · PubMed · Cited by 16
Self-citation
Cited by
Gut microbiota modulation of chemotherapy efficacy and toxicity
Alexander, J. L., Wilson, I. D., Teare, J., Marchesi, J. R., Nicholson, J. K., & Kinross, J. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.20 · Cited by 970
“Irinotecan causes severe diarrhoea in up to 40% of patients, requiring dose reduction and, in many cases, premature termination of the drug 42 .”
Innocenti, F., Undevia, S. D., Iyer, L., Xian Chen, P., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramírez, J., Rudin, C. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.173 · Cited by 964
Camptothecin: current perspectives
Thomas, C. J., Rahier, N. J., & Hecht, S. M. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2003.11.036 · Cited by 451
Drummond, D. C., Noble, C. O., Guo, Z., Hong, K., Park, J. W., & Kirpotin, D. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4007 · Cited by 380
Köhne, C.-H., van Cutsem, E., Wils, J., Bokemeyer, C., El-Serafi, M., Lutz, M. P., Lorenz, M., Reichardt, P., Rückle-Lanz, H., Frickhofen, N., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.546 · Cited by 331
Self-citation
Metadata
- Authors
- Vanhoefer, U., Harstrick, A., Achterrath, W., Cao, S., Seeber, S., & Rustum, Y. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-03-01
- Volume
- 19
- Issue
- 5
- Pages
- 1501-1518
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1927999720
- Cited by
- 326
- References
- 106
- FWCI
- 13.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.